The involvement of kallikrein-kinin system in diabetes type I (insulitis)

被引：44

作者：

Zuccollo, A

Navarro, M

Frontera, M

Cueva, F

Carattino, M

Catanzaro, OL

机构：

[1] Univ Buenos Aires, Fac Farm & Bioquim, PROSIVAD, CONICET, RA-1113 Buenos Aires, DF, Argentina

[2] Hosp Israelita Ezrah, Buenos Aires, DF, Argentina

来源：

IMMUNOPHARMACOLOGY | 1999年 / 45卷 / 1-3期

关键词：

insulitis; kallikrein-kinin; B-1; antagonist;

D O I：

10.1016/S0162-3109(99)00149-6

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Islet inflammation or insulitis is followed by selective destruction of the insulin secreting B-cell. Animal models of insulin-dependent diabetes mellitus (IDDM) have been used to characterize more fully insulitis, and our results with C57/BL/Ks mdb with low doses of streptozotocin (STZ) confirmed the disease. B-1 receptor antagonist [Leu(8)]des-Arg(9)-BK has shown a significant effect on diabetic glycemia and renal control parameters. Compared to insulin, the drug was effective to prevent the insulitis and the renal damage. On the other hand, B-2 receptor antagonist (HOE 140) and ACE-I (captopril) were only able to control the urinary diabetic proteinuria. (C) 1999 Elsevier Science B.V. All rights reserved.

引用

页码：69 / 74

页数：6

共 13 条

[1]

COOKE A, 1990, CURR TOP MICROBIOL, V164, P125

[2]

DECKERT T, 1981, DIABETOLOGIA, V21, P178

[3]

GEPS W, 1965, DIABETES, V14, P619

[4] BRADYKININ RECEPTORS - PHARMACOLOGICAL PROPERTIES AND BIOLOGICAL ROLES [J].